

Andrew Haydon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4612932/publications.pdf>

Version: 2024-02-01

69
papers

7,169
citations

201674

27
h-index

138484

58
g-index

70
all docs

70
docs citations

70
times ranked

9237
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. <i>New England Journal of Medicine</i> , 2018, 378, 1789-1801.	27.0	1,441
2	Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1813-1823.	27.0	1,192
3	Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. <i>Science Translational Medicine</i> , 2016, 8, 346ra92.	12.4	1,036
4	Investigation of the Safety of Irreversible Electroporation in Humans. <i>Journal of Vascular and Interventional Radiology</i> , 2011, 22, 611-621.	0.5	408
5	Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo. <i>JAMA Oncology</i> , 2020, 6, 519.	7.1	287
6	Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. <i>New England Journal of Medicine</i> , 2020, 383, 1139-1148.	27.0	256
7	Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. <i>Lancet</i> , The, 2022, 399, 1718-1729.	13.7	236
8	Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. <i>Gut</i> , 2019, 68, 663-671.	12.1	234
9	Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF ^{V600E} Mutant Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3441-3449.	1.6	226
10	Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 510-520.	10.7	183
11	3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. <i>Lancet Oncology</i> , The, 2018, 19, 562-578.	10.7	133
12	Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in Patients With Metastatic, Chemotherapy-Refractory, Wild-Type K-RAS Colorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 2477-2484.	1.6	122
13	Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma. <i>JAMA Oncology</i> , 2021, 7, 744.	7.1	110
14	Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. <i>Lancet Oncology</i> , The, 2021, 22, 836-847.	10.7	104
15	Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. <i>British Journal of Cancer</i> , 2017, 116, 1558-1563.	6.4	91
16	Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003620.	8.4	88
17	Associations of alcohol intake, smoking, physical activity and obesity with survival following colorectal cancer diagnosis by stage, anatomic site and tumor molecular subtype. <i>International Journal of Cancer</i> , 2018, 142, 238-250.	5.1	83
18	Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy. <i>British Journal of Cancer</i> , 2017, 117, 921-924.	6.4	81

#	ARTICLE	IF	CITATIONS
19	Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 2140-2150.	1.6	68
20	Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2019, 116, 148-157.	2.8	64
21	Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma. , 2020, 8, e001681.		57
22	A Randomized Controlled Trial of a Nurse-Led Supportive Care Package (SurvivorCare) for Survivors of Colorectal Cancer. <i>Oncologist</i> , 2016, 21, 1014-1023.	3.7	56
23	Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 2258-2264.	1.6	52
24	Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 358-365.	3.3	51
25	Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 701-710.	10.7	50
26	Tumour mutation status and sites of metastasis in patients with cutaneous melanoma. <i>British Journal of Cancer</i> , 2017, 117, 1026-1035.	6.4	46
27	Metastatic pathways in patients with cutaneous melanoma. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 13-27.	3.3	38
28	Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy. , 2021, 9, e003066.		34
29	Low-dose cyclophosphamide enhances antigen-specific CD4+ T cell responses to NY-ESO-1/ISCOMATRIX _® vaccine in patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 507-518.	4.2	31
30	Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders. , 2021, 9, e002121.		30
31	The Upper Gastrointestinal Cancer Registry (UGICR): a clinical quality registry to monitor and improve care in upper gastrointestinal cancers. <i>BMJ Open</i> , 2019, 9, e031434.	1.9	27
32	Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. <i>British Journal of Cancer</i> , 2021, 124, 574-580.	6.4	27
33	Complete Pathological Response After Neoadjuvant Long-Course Chemoradiotherapy for Rectal Cancer and Its Relationship to the Degree of T3 Mesorectal Invasion. <i>Diseases of the Colon and Rectum</i> , 2016, 59, 361-368.	1.3	23
34	Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 5-12.	1.1	22
35	ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. <i>BMC Cancer</i> , 2016, 16, 339.	2.6	15
36	Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC. <i>Clinical Lung Cancer</i> , 2021, 22, e425-e430.	2.6	15

#	ARTICLE	IF	CITATIONS
37	The acceleration of ageing in older patients with cancer. <i>Journal of Geriatric Oncology</i> , 2021, 12, 343-351.	1.0	14
38	Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy. <i>British Journal of Cancer</i> , 2018, 118, 1289-1295.	6.4	13
39	The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. <i>European Journal of Cancer</i> , 2021, 151, 72-83.	2.8	12
40	Stereotactic Radiation Therapy Combined With Immunotherapy Against Metastatic Melanoma: Long-Term Results of a Phase 1 Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 150-156.	0.8	11
41	An update on adjuvant systemic therapies in melanoma. <i>Melanoma Management</i> , 2019, 6, MMT28.	0.5	10
42	Non-aspirin non-steroidal anti-inflammatory drugs in colorectal cancer: a review of clinical studies. <i>British Journal of Cancer</i> , 2022, 127, 1735-1743.	6.4	10
43	Towards new models of cancer care in Australia: lessons from Victoria's response to the COVID-19 pandemic. <i>Internal Medicine Journal</i> , 2020, 50, 1282-1285.	0.8	9
44	Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III BRAF-mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9590-9590.	1.6	9
45	Primary Tumor Thickness is a Prognostic Factor in Stage IV Melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 90-94.	1.3	8
46	Dabrafenib plus trametinib (D + T) as adjuvant treatment of resected BRAF-mutant stage III melanoma: Findings from the COMBI-AD trial analyzed based on AJCC 8 classification.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9591-9591.	1.6	8
47	Lifetime alcohol intake, drinking patterns over time and risk of stomach cancer: A pooled analysis of data from two prospective cohort studies. <i>International Journal of Cancer</i> , 2021, 148, 2759-2773.	5.1	7
48	Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy. <i>ANZ Journal of Surgery</i> , 2021, 91, 3-13.	0.7	7
49	Immunohistochemistry testing for mismatch repair deficiency in Stage 2 colon cancer: A cohort study of two cancer centres. <i>International Journal of Surgery</i> , 2018, 51, 71-75.	2.7	6
50	Treatment of High Risk Resected Melanoma in Australia: Current Landscape and Practises. <i>Australasian Journal of Dermatology</i> , 2020, 61, 203-209.	0.7	4
51	Factors Explaining Socio-Economic Inequalities in Survival from Colon Cancer: A Causal Mediation Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1807-1815.	2.5	4
52	The Victorian Melanoma Service: A 20-year review of an Australian multidisciplinary cancer service. <i>Australasian Journal of Dermatology</i> , 2016, 57, 235-237.	0.7	3
53	Effect of Aspirin on Melanoma Incidence in Older Persons: Extended Follow-up of a Large Randomized Double-blind Placebo-controlled Trial. <i>Cancer Prevention Research</i> , 2022, 15, 365-375.	1.5	3
54	Prediagnosis alcohol intake and metachronous cancer risk in cancer survivors: A prospective cohort study. <i>International Journal of Cancer</i> , 2021, 149, 827-838.	5.1	2

#	ARTICLE	IF	CITATIONS
55	Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma – Authors' reply. <i>Lancet Oncology</i> , 2021, 22, e343-e344.	10.7	2
56	Patients'™ Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa107.	2.9	2
57	383 – Durable responses with intratumoral electroporation of plasmid interleukin 12 plus pembrolizumab in patients with advanced melanoma progressing on an anti-PD-1 antibody: updated data from keynote 695. , 2021, 9, A417-A417.		2
58	Concordance of somatic mutational profile in multiple primary melanomas. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 592-603.	3.3	1
59	Reply to E. Hindi – and K.R. Hess. <i>Journal of Clinical Oncology</i> , 2019, 37, 1356-1358.	1.6	1
60	Caution in the age of optimism; a salient lesson in advanced melanoma. <i>Annals of Translational Medicine</i> , 2020, 8, 720-720.	1.7	1
61	Reply to E. Hindi – . <i>Journal of Clinical Oncology</i> , 2021, 39, 944-946.	1.6	1
62	Salvage Treatment Using Anti – PD-1/CTLA-4 Immunotherapy After Failure of Neoadjuvant Chemotherapy in Microsatellite Instable Gastroesophageal Carcinoma. <i>Oncologist</i> , 2021, 26, 461-464.	3.7	1
63	547 – CERPASS: A randomized, controlled, open-label, phase 2 study of cemiplimab ± RP1 in patients with advanced cutaneous squamous cell carcinoma. , 2021, 9, A577-A577.		1
64	Inferior vena caval leiomyosarcoma in a patient with past bilateral retinoblastoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2008, 4, 181-183.	1.1	0
65	P2.02-052 Does Delay from Diagnosis to Start of Radiotherapy, or Modified Comorbidity Score Impact Survival in Curatively Treated Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, S879-S880.	1.1	0
66	783 Lifetime alcohol intake and stomach cancer risk: a pooled analysis of two prospective cohort studies. <i>International Journal of Epidemiology</i> , 2021, 50, .	1.9	0
67	341 – A phase Ib expansion cohort of pixatimod plus nivolumab in previously treated, microsatellite stable metastatic colorectal cancer (MSS mCRC). , 2021, 9, A367-A367.		0
68	340 – A phase Ib study of the safety and tolerability of pixatimod plus nivolumab in subjects with advanced solid tumors with an expansion cohort in metastatic pancreatic adenocarcinoma (mPDAC). , 2021, 9, A366-A366.		0
69	Association between hypertension and cutaneous melanoma, and the effect of aspirin: extended follow-up of a large randomised controlled trial. <i>Cancer Epidemiology</i> , 2022, 79, 102173.	1.9	0